That's why you are not BP. How many BPs made offers during this type of uncertainty in the past? It could happen, but don't bet on it.
Look, these are 24-month follow-up data. You can't contribute SAEs that far from their previous treatments to their previous treatments. That's called rationalization! I am inclined to believe lower 30mg/15mg would have better risk/benefit profile. However, I haven't seen 24-month safety data, I try not to make assumptions based on management's presentation ALONE especially their safety data presentation at ASH last year was so different from FDA's a few weeks later. There are many different ways to present data without being a liar - I understand the intricacy of clinical data. Remember, PACE follow-up safety data had been available to them all along as they accumulated in the past year, so it shouldn't be a surprise to them like in blinded trial! I want to see the data myself before making any judgement.
